What types of tumors is Tislelizumab suitable for?

Tislelizumab (Tislelizumab) is an anti-programmed death receptor-1 (PD-1) monoclonal antibodies, by blocking the binding of PD-1 and its ligands, restore and enhance the body's immune system's ability to recognize and attack tumor cells, thereby achieving anti-tumor effects. As an immune checkpoint inhibitor, tislelizumab has shown good efficacy in the treatment of multiple solid tumors and has gradually become one of the important drugs in tumor immunotherapy.

Tislelizumab is widely used in the treatment of non-small cell lung cancer (NSCLC). Especially for patients with advanced or metastatic non-small cell lung cancer, tislelizumab can be used as a single agent or in combination with chemotherapy to effectively prolong the progression-free survival and overall survival of patients. In addition, tislelizumab also provides a new treatment option for some patients who cannot receive chemotherapy.

Tislelizumab is also approved to treat classical Hodgkin lymphoma (cHL). In patients who have failed or relapsed with traditional treatments, tislelizumab has demonstrated significant anti-tumor activity and helped improve patients' condition and quality of life. The approval of this indication further enriches the treatment options for refractory lymphoma.

Tislelizumab has also shown certain efficacy in a variety of solid tumors such as esophageal cancer, hepatocellular carcinoma, and gastric cancer, and more clinical research and indication expansion are underway. Overall, tislelizumab, with its unique immunomodulatory mechanism, provides new treatment hope for patients with various tumors and has become one of the key drugs in the current field of immuno-oncology treatment.

Reference materials:https://www.drugs.com/donanemab.html